Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
Rhea-AI Summary
Bio-Path Holdings, Inc. will announce its first quarter 2024 financial results on May 15, 2024. The company specializes in developing cancer drugs using its proprietary DNAbilize® antisense RNAi nanoparticle technology. Bio-Path's lead product candidate, prexigebersen, is in Phase 2 study for blood cancers, and BP1001-A is in Phase 1/1b study for solid tumors. The company is also evaluating BP1002 for blood cancers and solid tumors, with an IND expected to be filed for BP1003. Bio-Path will host a live conference call to discuss the financial results and provide a business overview.
Positive
- Bio-Path Holdings to announce financial results for the first quarter of 2024, showcasing transparency and accountability to investors.
Negative
- Investors may scrutinize the financial results closely, looking for signs of financial health and growth potential for the company in the competitive biotechnology market.
News Market Reaction
On the day this news was published, BPTH declined 8.00%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.
To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
When will Bio-Path Holdings announce its first quarter 2024 financial results?
What technology does Bio-Path Holdings use to develop cancer drugs?
What are the lead product candidates of Bio-Path Holdings and in which studies are they involved?
Where can I access the live conference call discussing the financial results?
